40
Participants
Start Date
April 30, 2015
Primary Completion Date
July 9, 2020
Study Completion Date
July 9, 2020
brentuximab vedotin
is 1.8 mg/kg administrated by IV infusion
Cyclophosphamide
1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
Adriamycin
35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
Oncovin
1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
Bleomycin
10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
Etoposide
200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
Procarbazine
100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
Prednisone
40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
G-CSF
5 µg/kg/j, SC, D9 until GB 1.0x109/L
30 Grays
30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
Institut Paoli Calmette, Marseille
Hôpital de la Conception, Marseille
Centre François Baclesse, Caen
CHU de Dijon - Hôpital le Bocage, Dijon
I.U.C.T Oncopole, Toulouse
Polyclinique Bordeaux Nord, Bordeaux
Hôpital Haut Lévêque, Pessac
CHU Montpellier - Saint ELOI, Montpellier
CHU Pontchaillou, Rennes
CHU Bretonneau, Tours
CHU de Nantes, Nantes
CHU Robert Debre, Reims
CHU de Brabois, Vandœuvre-lès-Nancy
CHRU Lille - Hôpital Claude Huriez, Lille
CH Perpignan, Perpignan
CHU de Strasbourg, Strasbourg
Centre Léon Bérard, Lyon
CHU Lyon Sud, Pierre-Bénite
Clinique Victor Hugo, Le Mans
CH de Chambéry, Chambéry
Hôpital Cochin, Paris
Hôpital Saint Louis, Paris
Hôpital de la Pitié Salpétrière, Paris
Centre Henri Becquerel, Rouen
Hôpital André Mignot, Le Chesnay
CHU de Limoges, Limoges
CH Sud Francilien, Corbeil-Essonnes
Hôpital Henri Mondor, Créteil
Gustave Roussy Cancer Campus, Villejuif
CH Victor Dupouy, Argenteuil
The Lymphoma Academic Research Organisation
OTHER